Piramal Enterprises (Delisted) share news and announcements
BSE: 500302Finance
Formerly Piramal Healthcare
Last traded ₹1,124.20 on 22 Sep 2025
Delisted on 16 Jan 2026.
Piramal Enterprises share news and announcements
3,280 announcements, routine notices left out, newest first. Page 61 of 66.
Nov 2010
4 Nov · Meeting
Members of the Company will consider to approve by way of Postal Ballot the following Resolutions: 1. Accorded for the buyback by ....3 Nov · Disclosure
Piramal Healthcare Ltd has submitted the disclosure under Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 to BSE:3 Nov · Disclosure
Surinder Kaul has submitted the disclosure under Regulation 13(4) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 to BSE2 Nov · Disclosure
Narayan has submitted the disclosure under Regulation 13(4) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 to BSE
Oct 2010
30 Oct · Disclosure
Piramal Healthcare Ltd has submitted the disclosure under Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 to BSE:22 Oct · Board approves Buy Back
Board of Directors of the Company at its meeting held on October 22, 2010, after considering various alternatives, including Interim Dividend ....22 Oct · Buyback
Board of Directors at its meeting held on October 22, 2010 after considering various alternatives, including Interim Dividend and/or Buy-back of Shares, and considering the fact that Buy-back is a better tax efficient method of maximizing value to shareholders, have approved Buy-back proposal for purchase by the Company of a maximum of 4,18,02,629 equity shares of face value Rs.2 each (representing 20% of the total number of shares), from the shareholders of the Company on a proportionate basis through the Tender Offer route as prescribed under the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 1998 (the "Buy-back Regulations") at a price of Rs.600 (Rupees six hundred) per equity share, aggregating to Rs.2,508 Crores in accordance with the provisions of the Companies Act, 1956 and the Buy-back Regulations (the "Buy-back"). The Buy-back would be subject to approval of the shareholders by way of a Special Resolution through Postal Ballot and all other applicable statutory approvals. The public announcement setting out the detailed timeline for the Buy-back and other statutory details will be released in due course in accordance with the Buy-back Regulations. The Buy-back process is expected to be completed by February 2011, subject to requisite approvals. The Board has formed a Committee of Directors (the "Buy-back Committee") and has delegated its powers to the Buy-back Committee to do all such acts, deeds, matters and things as it may, in its absolute discretion, deem necessary, expedient, usual or proper in connection with the Buy-back.22 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 75201 lacs for quarter ending on 30-SEP-2010 against Rs. 99999 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 1254044 lacs for the quarter ending on 30-SEP-2010 against Rs. 10627 lacs for the quarter ending on 30-SEP-2009.22 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 54004 lacs for quarter ending on 30-SEP-2010 against Rs. 70770 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 1256998 lacs for the quarter ending on 30-SEP-2010 against Rs. 11422 lacs for the quarter ending on 30-SEP-2009.19 Oct · Updates on ensuing Board Meeting on Oct 22, 2010
With reference to the earlier announcement dated October 13, 2010 regarding the meeting of the Board of Directors of the Company will be held on October 22, 2010 to consider and take on ....13 Oct · Board meeting
To consider and take on record the Financial Results (consolidated and standalone) of the Company for the 2nd quarter and half-year ended September 30, 2010.13 Oct · Results
Meeting of the Board of Directors of the Company will be held on October 22, 2010, to consider and take on record the Financial Results (consolidated ....
Sep 2010
8 Sep · Completion of the Sale of its Domestic Formulations Business to Abbott Healthcare Pvt Ltd